Graves’病患者肝纤维化指标测定的意义

Changes of Hepatofibrosis Markers In Graves' Disease

目的:探讨G raves’D isease(GD)与肝纤维化指标的关系及其可能的机理。方法:用放射免疫分析(R IA)检测GD患者治疗前40例,治疗后35例和30例健康成人的血清Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原(PCⅢ)、透明质酸(HA)、层粘连蛋白(LN)的含量。结果:GD患者血清中Ⅳ-C、PCⅢ含量比正常对照组显著性升高(P<0.01),治疗后甲状腺激素水平下降,Ⅳ-C、PCⅢ含量也随之下降(与治疗前比较P<0.01),HA、LN在以上各组中无显著性差异(P>0.05)。结论:GD患者甲状腺激素水平升高时,Ⅳ-C、PCⅢ含量也增高,在判断肝纤维化时应注意有无合并GD。

Objective To study the changes of hepatofibrosis markers （ Ⅳ - C, PC Ⅲ, HA, LN） in Graves＇ disease. Methods Serum Levels of hepatofibrosis were measured with RIA in 40 patients with Graves＇ disease （GD） before any treatment and 35 patients with Graves＇ disease after successful anti - thyroid drug therapy as well as in 30 controls. Results The serum Ⅳ - C and Pcm levels in GD patients were significant higher than those in controls before treatment （P 〈 0.01 ）. After successful treatment, the Ⅳ - C, PC Ⅲ levels dropped markedly （vs before treatment, P 〈 0.01 ）. However, there were no significant differences among the serum HA, LN levels in all the subjects tested. Conclusion Serum levels of Ⅳ - C and PC Ⅲ increased markedly with hyperthyroidim. When Ⅳ - C and PC Ⅲ levels were taken for assessment of degree of hepatofibeosis, GD must be ruled out first.